Please provide your email address to receive an email when new articles are posted on . The type of arteriovenous access placement, graft or fistula, used first in older patients receiving ...
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it will host ...
Please provide your email address to receive an email when new articles are posted on . Published findings report that, for vascular access in hemodialysis, the creation of an arteriovenous fistula ...
DURHAM, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
(Wednesday, June 14, 2017 -- Toronto) A new, minimally invasive system which uses radiofrequency energy instead of open surgery to create access for patients needing hemodialysis is reliable, with ...
Central venous catheters are currently the primary method of vascular haemodialysis access used by paediatric nephrologists in the USA. However, new data from Ma and colleagues suggest that in ...
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Market Report for AV Fistula Needles 2017 - MedCore" report to their offering. An AV fistula needle enables access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results